创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

WEI Xiayu, SHEN Jingling, Zhao Haiyang, LI Xiaokun, ZHANG Jinsan. Research Progress on Fibroblast Growth Factor Receptors in Cancer and Antitumor Targeting Drugs[J]. Progress in Pharmaceutical Sciences, 2020, 44(8): 609-620.
Citation: WEI Xiayu, SHEN Jingling, Zhao Haiyang, LI Xiaokun, ZHANG Jinsan. Research Progress on Fibroblast Growth Factor Receptors in Cancer and Antitumor Targeting Drugs[J]. Progress in Pharmaceutical Sciences, 2020, 44(8): 609-620.

Research Progress on Fibroblast Growth Factor Receptors in Cancer and Antitumor Targeting Drugs

  • Fibroblast growth factor receptors (FGFRs) belong to a large superfamily of receptor tyrosine kinases. FGFR signaling participates in key cellular activities such as cell proliferation, differentiation and survival, and plays crucial roles in multiple physiological processes during embryonic development, adult tissue repair and metabolic regulation. Dysregulation of FGFR caused by gene amplification, gene mutation and gene fusion has also been implicated in many types of human cancers. Therefore, FGFR has become a promising potential target in cancer treatment. Currently, substantial progress has been made in the research and application of targeting drugs for FGFR, some of which have been approved for clinical treatment or are under clinical trials. Collectively, the FGFR family members, its abnormal expression in tumors, and the development of drugs targeting FGFR are summarized in the present article.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return